Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Urology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Bladder Carcinoma Clinical Trials

A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (268) clinical trials

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

This is an open-label, multicenter trial to collect long-term safety and efficacy data and to provide ongoing access to tisotumab vedotin for patients with solid tumors who have completed a tisotumab vedotin base trial.

Phase

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

PRIMARY OBJECTIVES: I. To compare RRC to ORC in terms of the difference in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core (QLQC)30 quality of life instrument assessed at baseline to day 30 after radical cystectomy (RC). II. To compare RRC to ORC in ...

Phase N/A

Evaluating Immune Therapy Durvalumab (MEDI4736) With Tremelimumab for Metastatic Non-transitional Cell Carcinoma of the Urinary Tract

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

Phase

Determinants of Bladder Cancer Recurrence Study (The DETER Study)

The purpose of this study is to learn how different lifestyle factors, such as cigarette smoking and body weight, change after a diagnosis of bladder cancer, and how they influence who gets a bladder cancer recurrence and who does not.

Phase N/A

Focal Therapy for Prostate Cancer Using HIFU

Verification of a new therapy as favourable, or equivalent, in outcome to 'standard' care is ideally sought through comparison with another matched control group. Randomised controlled trials (RCTs) offer the best method for minimising systematic bias and revealing the true effect of an intervention or drug. However, RCTs involving treatments ...

Phase N/A

Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)

Bladder cancer (BC), the second most common urological malignancy, is an important public health issue. One of the main challenges in the treatment of bladder cancer if the prevention of recurrences of non-invasive tumors, which is also associated with significant costs. The current study will investigate optimal treatment of patients ...

Phase

Precise Treatment System of Biliary Malignancies Based on Special Disease Database

Malignant tumors of biliary system lack standard treatment and precise prognosis assessment methods. This study including 12 hospitals, collecting clinical and follow-up data of patients with biliary malignant tumors including cholangiocarcinoma and gallbladder carcinoma in recent 10 years, aim to build a special disease database, then use Bayesian networks and ...

Phase N/A

Blue Light Cystoscopy With Cysview Registry

Data will be captured on specific patient types undergoing Blue Light Cystoscopy with Cysview for known or suspected non-muscle invasive bladder cancer. Specific clinical questions will be asked. What is the incremental detection rate with Blue Light Cystoscopy with Cysview over conventional white light cystoscopy in each of the seven ...

Phase N/A

MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer

Bladder cancer (BC) as the most common malignancy arising from the urinary tract continues to be a major health problem. This prospective non-randomized study will enroll 150 patients undergoing magnetic resonance imaging (MRI) at different stages of their diagnostic and therapeutical process. The enrolled patients with suspected BC (BC) based ...

Phase N/A

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Primary Objective To estimate the proportion of patients with pathological downstaging to <pT2 after neoadjuvant therapy with pembrolizumab in combination with gemcitabine and cisplatin in patients with MIBC Hypothesis: The rate of pathologic downstaging to <pT2 will improve compared to historical controls Secondary Objectives To estimate the proportion of patients ...

Phase